Clinical translation of ex vivo sentinel lymph node mapping for colorectal cancer using invisible near-infrared fluorescence light


ABSTRACT

Background

Sentinel lymph node (SLN) mapping in colorectal cancer may have prognostic and therapeutic significance, however, currently available techniques are not optimal. We hypothesized that the combination of invisible near-infrared (NIR) fluorescent light and *ex vivo* injection could solve remaining problems of SLN mapping in colorectal cancer.

Methods

The FLARE™ imaging system was used for real-time identification of SLNs after injection of the NIR lymphatic tracer HSA800 in the colon and rectum of (n = 4) pigs. A total of 32 SLN mappings were performed *in vivo* and *ex vivo* after oncologic resection using an identical injection technique. Guided by these results, SLN mappings were performed in *ex vivo* tissue specimens of 24 consecutive colorectal cancer patients undergoing resection.

Results

Lymph flow could be followed in real-time from the injection site to the SLN using NIR fluorescence. In pigs, the SLN was identified in 32/32 (100%) of SLN mappings under both *in vivo* and *ex vivo* conditions. Clinically, SLNs were identified in all patients (n = 24) using the *ex vivo* strategy within 5 minutes after injection of fluorescent tracer. Nine patients showed lymph node involvement (N1-disease). In one patient, a 3 mm mesenteric metastasis was found adjacent to a tumor-negative SLN.

Conclusions

The current pilot study shows proof of principle that *ex vivo* NIR fluorescence-guided SLN mapping can provide high-sensitivity, rapid, and accurate identification of SLNs in colon and rectum. This creates an experimental platform to test optimized, non-FDA-approved NIR fluorescent lymphatic tracers in a clinical setting.
INTRODUCTION

The prognosis and quality of life for patients suffering from colorectal cancer (CRC) depends on the extent and quality of surgical treatment. Apart from tumor characteristics (i.e. stage, differentiation grade), complete surgical removal with en bloc regional lymphadenectomy is pivotal for patient prognosis. Metastatic spread to regional lymph nodes is one of the most important prognostic factors and determines the need for adjuvant chemotherapy. The sentinel lymph node (SLN) is the first lymph node that receives lymphatic drainage from a tumor, and identification of the SLN and analysis for tumor involvement should predict the status of the remaining lymph nodes. The SLN procedure is regarded standard of care in the treatment of breast cancer\textsuperscript{1,2} and melanoma.\textsuperscript{3} However, its added value in colorectal cancer has not yet been established.

Retrospective studies on micrometastatic disease in CRC and the risk of recurrence are conflicting.\textsuperscript{4-6} Our group has previously shown that ultra-staging of lymph nodes with RT-PCR identifies a subgroup of pN0 patients with an inferior prognosis.\textsuperscript{7} However, this methodology is labor intensive and not used routinely. Identifying the SLN in the surgical specimen provides the pathologist with an opportunity to optimally stage the lymphatic basin beyond standard H&E analysis of the regional nodes.\textsuperscript{8} Published results on identifying SLN in CRC show variable success rates ranging from 58 to 100 percent.\textsuperscript{9-17} Consequently, there is ample room for improvement of mapping methodology.

In the majority of published studies of CRC patients, subserosal, circumferential, and peri-tumoral injection of the visible dye isosulfan blue has been used, both \textit{in vivo} and \textit{ex vivo}.\textsuperscript{11,12,14,18} Isosulfan blue is distributed rapidly through the afferent lymphatic channels, however, due to its small size, the dye particles can readily diffuse through the true SLN to second and third tier nodes (a total of up to 21 “sentinel” nodes are reported).\textsuperscript{15} Isosulfan blue also stains tissue in an unnatural color and provides poor overall contrast.

Dyes that emit fluorescence in the invisible, near-infrared (NIR) portion of the electromagnetic spectrum (700 to 900 nm) have several advantages for SLN mapping. NIR light penetrates relatively deep into living tissue, and tissue itself has low autofluorescence in the NIR, resulting in a high signal-to-background ratio.\textsuperscript{19} Since NIR light is not visible to the human eye, there is no change to the look of the surgical field. Several clinical studies have been published on SLN mapping in breast cancer, gastric cancer and colon cancer, using the clinically available NIR probe indocyanine green.\textsuperscript{20-24} However, these studies were performed using imaging systems that display the NIR signal without the visible image as a surgical anatomical reference. Our group has developed a system (FLARE™) that is capable of displaying NIR signal and visible image (captured by a color video camera) simultaneously and can superimpose the NIR signal over the color image.\textsuperscript{25,26}
Previously, our group reported the use of NIR light for real-time intraoperative SLN mapping of the gastrointestinal tract.\textsuperscript{27, 28} These and earlier studies show clear advantages of NIR imaging over the conventional blue dyes.\textsuperscript{29} Of published organic molecules, the NIR fluorophore HSA800 emerged as the molecule with the best overall performance with respect to entry to the lymphatics, flow to the SLN, retention in the SLN, fluorescence yield, and reproducibility. Since HSA800 cannot be translated to the clinic without a long and costly regulatory process, we hypothesized that ex \textit{vivo} SLN mapping in colon and rectal cancer could provide all of the benefits of NIR fluorescence imaging over visible blue dyes, without the need for regulatory approval, and without risk to the patient.

**MATERIALS AND METHODS**

**Lymphatic tracers**

The preparation of HSA800 (IRDye 800CW conjugated to human serum albumin) has been described in detail previously.\textsuperscript{27} The ratio of fluorophore (IRDye 800CW; LI-COR, Lincoln, USA) to albumin (HSA) was 3:1, estimated using the extinction coefficients of HSA (\(\varepsilon_{280\text{nm}} = 32,900 \text{ M}^{-1}\text{cm}^{-1}\)) and CW800 (\(\varepsilon_{780\text{nm}} = 240,000 \text{ M}^{-1}\text{cm}^{-1}\)) in PBS. Peak absorbance and emission of HSA800 were 778 nm and 795 nm, respectively. A stock solution of 10 \(\mu\text{M}\) (in pig) or 50 \(\mu\text{M}\) (in human) HSA800 in phosphate-buffered saline (PBS), pH 7.4 was used for all injections.

**Real-time NIR fluorescence imaging**

Preclinical SLN mapping was performed using the FLARE\textsuperscript{™} image-guided surgery system as described in detail previously.\textsuperscript{26} The system is shown schematically in Figure 1. It consists of two wavelength isolated light sources: a “white” light source, generating 40,000 lx of 400-650 nm light and a “near infrared” light source, generating 12.5 mW/cm\(^2\) 760 nm light over a 15 cm field of view. Color video and NIR fluorescence images are simultaneously acquired and displayed in real-time using custom optics and software that separate the color video and NIR fluorescence images.\textsuperscript{26} A pseudo-colored (lime green) merged image of the color video and NIR fluorescence images is also displayed. Clinical SLN mapping was performed using a miniaturized version of FLARE\textsuperscript{™} (Mini-FLARE\textsuperscript{™}), which is described in detail in Chapter 6, with settings of 20,000 lx of 400-650 nm “white” light and 7 mW/cm\(^2\) of 760 nm NIR light.
Animal model systems

Animals were housed in an AAALAC-certified facility staffed by full-time veterinarians and were studied under the supervision of an approved institutional protocol. This protocol adhered to the “Guide for the Care and Use of Laboratory Animals”, NRC 1996. 4 female Yorkshire pigs were purchased at 35 kg from E.M. Parsons and Sons (Hadley, USA). All animals acclimated to the animal facility for at least 48 hr prior to experimentation. Anesthesia was induced with 4.4 mg/kg intramuscular Telazol (Fort Dodge Labs, Fort Dodge, USA). The animal was then intubated and anesthesia was maintained with 2% isoflurane (Baxter Healthcare Corporation, Deerfield, USA). ECG, heart rate, oxygen saturation and body temperature were monitored throughout the experiment. At the end of each experiment, euthanasia was induced by rapid intravenous injection of 10 mL of Fatal-Plus (Vortech Pharmaceuticals, Dearborn, USA), a method consistent with the recommendation of the Panel on Euthanasia of the American Veterinary Medical Association.
Preclinical sentinel lymph node mapping *in vivo* vs. *ex vivo*

SLN mapping was performed using a 1 cc syringe equipped with a 27-gauge, ½” needle. Each injection consisted of 0.1 cc of HSA800 solution injected subserosally, with the needle bevel facing upwards. The injection site was then gently massaged to stimulate lymphatic flow through increased hydrostatic pressure.

All animals received multiple injections at separate locations in the colon and rectum. For each condition (*in vivo* and *ex vivo*) 8 injections were performed in colon and 8 injections were performed in the rectum, for a total of 32 injections. The NIR fluorescence signal was monitored using the FLARE™ system and the SLN identified by watching uninterrupted lymphatic flow reach the first lymph node in real-time. After successful identification, the suspected lymph node was resected under fluorescence guidance, fixed in 2% paraformaldehyde for 12 hours, frozen in LN$_2$ using Tissue-Tek OCT, cryo-sectioned at 10 µm, and analyzed by hematoxylin and eosin (H&E) staining.

After the *in vivo* injections, a subtotal colectomy and a total mesorectal excision (TME) were performed. The resected bowel specimens were placed on a table and at locations that were not injected *in vivo*, 0.1 cc of HSA800 was injected subserosally, identical to the technique used for *in vivo* injections. Tissue samples were also collected and processed for histology as described above.

Time needed to identify the SLN was compared between *in vivo* and *ex vivo* conditions using an unpaired t-test. Assumption of equal variances was confirmed by Levene’s test. Statistical analyses, performed using SPSS software version 17.0 (SPSS Inc., Chicago, USA), were two-tailed and p < 0.05 was considered significant.

**Translation to the clinic**

Twenty-four consecutive patients undergoing curative intended surgery for colorectal cancer were included. This study was approved by the Leiden University Medical Center Medical Ethics Committee and performed in accordance with the ethical standards of the Helsinki Declaration of 1975. All patients underwent a standard oncological resection including lymphadenectomy. In case of colon cancer, a segmental colonic resection was performed; in case of rectal cancer, a resection following the principles of the total mesorectal excision (TME) was performed. Directly following resection, bowel segments were delivered fresh to the department of pathology, where the specimen was opened anti-mesenterically by the pathologist. In rectal cancer, surgical quality audit protocol prohibits altering the perirectal fat in any way. Consequently, in rectal cancer, the specimen was opened no further than the rectosigmoid junction. 1 cc of 50 µM HSA800 was injected submucosally circumferentially with a 5 mm margin around the tumor and the injection site was massaged for 5 minutes. After 5 minutes, the specimen was inspected using Mini-FLARE™. Any fluorescent
hotspots were either marked with a suture or directly resected for separate fixation in 2% buffered formalin. The specimen was fixed using 2% buffered formalin for 24 h (colon) or 48 h (rectum). After fixation, fluorescent nodes were identified under direct NIR fluorescence guidance with the Mini-FLARE™ and the specimen was processed following the standard clinical protocol. For rectal cancer, the specimen was processed using the slicing technique as described by Quirke. All lymph nodes (sentinel and non-sentinel) were paraffin embedded and 4 µm sections were H&E stained and subsequently analyzed by microscope for the presence of tumor cells.

RESULTS

Preclinical NIR fluorescence-guided SLN identification and resection

In both \textit{in vivo} and \textit{ex vivo} conditions, all injections led to a successful identification of a SLN (Table 1). Shortly after massaging the injection site, lymphatic flow was visualized on the NIR fluorescence image (Figure 2). In all cases, lymphatic flow terminated, without interruption, in one or more lymph nodes.

In colon, we found no difference (Table 1) in the time needed to identify the SLN between \textit{in vivo} (56.4 sec on average) and \textit{ex vivo} (58.8 sec on average) conditions ($t = -0.111, p = 0.913$). In the rectum, however, \textit{ex vivo} injection lead to a significantly faster identification time for the SLN (26.8 sec on average) compared to \textit{in vivo} (54.1 sec; $t = 2.942, p = 0.011$). Mean time between resection of the bowel and \textit{ex vivo} injection was 25 min (range 10 to 57 min). All resected specimens ($n = 32$) were analyzed by H&E histology and confirmed to be lymph node tissue (Figure 2B).

<table>
<thead>
<tr>
<th>Organ</th>
<th>Number of Injections (n)</th>
<th>Successful Identifications (n, %)</th>
<th>Number of SLNs Identified (n)</th>
<th>Average Identification Time (sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In vivo</td>
<td>8</td>
<td>8 (100%)</td>
<td>9</td>
<td>56.4 ± 48.3</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>8</td>
<td>8 (100%)</td>
<td>8</td>
<td>58.8 ± 36.2</td>
</tr>
<tr>
<td>Rectum</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In vivo</td>
<td>8</td>
<td>8 (100%)</td>
<td>10</td>
<td>54.1 ± 16.3</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>8</td>
<td>8 (100%)</td>
<td>9</td>
<td>26.8 ± 21.3</td>
</tr>
</tbody>
</table>

Clinical \textit{ex vivo} NIR fluorescence-guided SLN mapping in colorectal cancer patients

Patient and tumor characteristics are listed in Table 2.

In a preliminary set of experiments on $n = 6$ clinical specimens, it was found that the subserosal injection technique that worked so well with normal pig specimens
did not provide reliable results with human tumor specimens (data not shown). Injecting subserosally and circumferentially around human tumors resulted in a larger injection site, which outshined lymph nodes close to the tumor. To overcome this problem, a submucosal injection technique was used.\textsuperscript{15, 31} It was also found that due to the thickness of human specimens versus normal pig specimens, a high concentration (50 µM) of HSA800 was optimal.

Using this optimized strategy, in all 24 consecutive patients, the procedure led to a successful detection of SLNs. An example of the NIR fluorescence images of the procedure in colon cancer is shown in Figure 3A. In rectal cancer, quality control dictates that the specimen is not altered prior to inking, fixation and slicing. As shown in Figure 3B, in rectal cancer, nodes were harvested successfully after mesorectal slicing. Based on pre- and post-fixation images, the formalin fixation process did not appear to alter NIR fluorescence of HSA800. On average, per specimen, 3.0 (range 1 – 5) SLNs were identified by NIR fluorescence (Table 2). On average, a total of 15.9 (range 8 – 31) lymph nodes were harvested per specimen. Histological analysis showed that 9 of 24 patients had lymph node metastases. In all but one of those cases, at least one of the SLNs contained tumor cells. In one patient, however, a small tumor deposit (3 mm) was found in the mesentery whereas the SLN was tumor-negative. Although no clear lymphatic tissue could be identified (Figure 4), pathological guidelines (WHO-classification sixth edition) require that this lesion be classified as a lymph node metastasis.

\textbf{DISCUSSION}

The presence of lymph node metastases in CRC patients is the most important prognostic factor and an indication for adjuvant chemotherapy. The presence of nodal involvement decreases 5-year survival rates by 25 to 35%. Long-term follow-up of adjuvant chemotherapy for patients with stage III colon cancer showed a survival benefit with a 22 to 33% relative reduction in mortality.\textsuperscript{32, 33} Therefore, adequate staging in order to select patients who may benefit from adjuvant chemotherapy treatment is a necessity. Moreover, patients without nodal disease (stage I/II) still develop recurrent tumors in up to 25% of the cases within 5 years after surgical resection of the primary tumor. This could be due to pathological understaging of the tissue specimen at the time of primary treatment. SLN mapping would be a useful method to circumvent this problem.\textsuperscript{11}

Contradicting studies have also been published, showing a high false negative rate of SLN mapping in colon cancer.\textsuperscript{34, 35} These so called skip metastases, a tumor negative SLN combined with a positive non-SLN, are an important limiting factor to the validity of the SLN procedure. In colorectal cancer, skip metastases rates of 3% - 60% are reported.\textsuperscript{11, 36} It has been suggested that these variable rates are caused by the
applied SLN identification technique, which could be overcome by a more reliable method of identifying the SLN.

The current study shows proof of principle that by using invisible NIR fluorescent light and an optimal contrast agent, identification of the lymphatic channels and the

**Figure 2. In Vivo and Ex Vivo SLN Mapping in Colon and Rectum:**

**A.** Identification of the SLN (arrows) in pig colon after in vivo (top row) or ex vivo (bottom row) injection (arrowheads) of 0.1 cc of 10 mM HSA800. Shown are the color video (left), NIR fluorescence (middle), and pseudo-colored (lime green) merge of the two (right).

**B.** Ex vivo identification of the SLN (arrow) after injection (arrowhead) of 0.1 cc of 10 mM HSA800 (top row). Resected negative (-) and positive (+) nodes in rectum (bottom row). Shown are the color video (left), NIR fluorescence (middle), and pseudo-colored (lime green) merge of the two (right). Note accumulation of the dye at the sinus entry site.

**C.** H&E histological staining of the (+) tissue section (100X magnification) from Figure 3A.
SLN is rapid and accurate. In the presented preclinical experiments in pigs, both *ex vivo* NIR fluorescence imaging of the SLN as well as *in vivo* imaging showed similar results. These preclinical results were successfully translated into a pilot clinical study in which the SLN was identified *ex vivo* in all patients. Whereas the NIR fluorescent signal of subserosal injections outshined lymph nodes located close to the tumor, submucosal injections showed superior results in patient specimens.

In one patient with three tumor-negative SLNs, a small tumor metastasis was found in the mesenteric fat, without any remnants of pre-existent lymphatic tissue (Figure 4). According to the WHO-classification, sixth edition, such tumor deposits are regarded as lymph node involvement. This is supported by the configuration of the lesion, being encapsulated and round. Since the lesion was completely effaced by tumor cells and lymphatic tissue was not observable, it is plausible that no lymphatic drainage could reach this node and in fact the NIR lymphatic tracer had bypassed this

---

**Figure 3. NIR Fluorescence-Guided SLN Mapping in Patients with Colorectal Cancer:** A. *Ex vivo* identification of a SLN (arrow) in the mesentery of the right hemicolon of a patient with a cecal adenocarcinoma after submucosal peritumoral injection (arrowhead) of 1 cc of 50 mM HSA800. Shown are the color video (left), NIR fluorescence (middle), and pseudo-colored (lime green) merge of the two (right). B. *Ex vivo* identification of a SLN (arrow) in the mesorectum of a patient with a rectal adenocarcinoma after submucosal peritumoral injection (arrowhead) of 1 cc of 50 mM HSA800. After 48 hours fixation in 2% buffered formalin, tissue specimen was sliced and imaged. Shown are the color video (left), NIR fluorescence (middle), and pseudo-colored (lime green) merge of the two (right).

---

**Figure 4. Palpable Metastatic Lesion Identified in the Mesenteric Fat:** H&E histological staining of a mesenteric metastasis (25X magnification) not identified as a SLN. No nodal tissue was observed.
### Table 2. Patient Characteristics and Results of Sentinel Lymph Node Mapping

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yr)</th>
<th>Body Mass Index</th>
<th>Tumor Location</th>
<th>Tumor Differentiation</th>
<th>Tumor Size (cm)</th>
<th>Tumor Stage</th>
<th>NIR-Identified SLNs</th>
<th>Tumor Positive SLNs</th>
<th>Total LN</th>
<th>Total LN+</th>
<th>False Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>80</td>
<td>24</td>
<td>Cecum</td>
<td>Moderate</td>
<td>6.0</td>
<td>T3</td>
<td>2</td>
<td>0</td>
<td>16</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>69</td>
<td>29</td>
<td>Cecum</td>
<td>Moderate</td>
<td>5.5</td>
<td>T3</td>
<td>3</td>
<td>0</td>
<td>20</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>66</td>
<td>21</td>
<td>Cecum</td>
<td>Moderate</td>
<td>6.7</td>
<td>T3</td>
<td>3</td>
<td>0</td>
<td>18</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>38</td>
<td>39</td>
<td>Cecum</td>
<td>Moderate</td>
<td>3.5</td>
<td>T4</td>
<td>2</td>
<td>0</td>
<td>20</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>92</td>
<td>27</td>
<td>Cecum</td>
<td>Moderate</td>
<td>4</td>
<td>T3</td>
<td>4</td>
<td>2</td>
<td>12</td>
<td>3</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>65</td>
<td>16</td>
<td>Cecum</td>
<td>Moderate</td>
<td>1.3</td>
<td>T2</td>
<td>5</td>
<td>0</td>
<td>12</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>68</td>
<td>21</td>
<td>Asc. Colon</td>
<td>Moderate</td>
<td>5</td>
<td>T4</td>
<td>5</td>
<td>1</td>
<td>24</td>
<td>5</td>
<td>No</td>
</tr>
<tr>
<td>8</td>
<td>67</td>
<td>35</td>
<td>Asc. Colon</td>
<td>Moderate</td>
<td>4</td>
<td>T3</td>
<td>3</td>
<td>0</td>
<td>31</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>9</td>
<td>75</td>
<td>26</td>
<td>Asc. Colon</td>
<td>Moderate</td>
<td>4</td>
<td>T3</td>
<td>3</td>
<td>0</td>
<td>11</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>10</td>
<td>67</td>
<td>37</td>
<td>Asc. Colon</td>
<td>Moderate</td>
<td>2.3</td>
<td>T2</td>
<td>2</td>
<td>0</td>
<td>11</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>11</td>
<td>67</td>
<td>26</td>
<td>Asc. Colon</td>
<td>Moderate</td>
<td>5</td>
<td>T2</td>
<td>3</td>
<td>0</td>
<td>11</td>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>77</td>
<td>24</td>
<td>Hepatic Flexure</td>
<td>Poor</td>
<td>4.7</td>
<td>T3</td>
<td>2</td>
<td>1</td>
<td>16</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>13</td>
<td>91</td>
<td>29</td>
<td>Hepatic Flexure</td>
<td>Moderate</td>
<td>3.8</td>
<td>T4</td>
<td>4</td>
<td>2</td>
<td>18</td>
<td>9</td>
<td>No</td>
</tr>
<tr>
<td>14</td>
<td>43</td>
<td>38</td>
<td>Hepatic Flexure</td>
<td>Moderate</td>
<td>4</td>
<td>T3</td>
<td>3</td>
<td>0</td>
<td>11</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>15</td>
<td>75</td>
<td>26</td>
<td>Hepatic Flexure</td>
<td>Moderate</td>
<td>4.5</td>
<td>T3</td>
<td>2</td>
<td>0</td>
<td>19</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>16</td>
<td>68</td>
<td>28</td>
<td>Transv. Colon</td>
<td>Moderate</td>
<td>2.5</td>
<td>T1</td>
<td>3</td>
<td>2</td>
<td>16</td>
<td>6</td>
<td>No</td>
</tr>
<tr>
<td>17</td>
<td>48</td>
<td>28</td>
<td>Sigmoid</td>
<td>Well</td>
<td>3</td>
<td>T2</td>
<td>5</td>
<td>1</td>
<td>10</td>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>18</td>
<td>33</td>
<td>21</td>
<td>Sigmoid</td>
<td>Moderate</td>
<td>4</td>
<td>T3</td>
<td>3</td>
<td>0</td>
<td>18</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>19</td>
<td>46</td>
<td>28</td>
<td>Sigmoid</td>
<td>Moderate</td>
<td>4.5</td>
<td>T3</td>
<td>3</td>
<td>0</td>
<td>14</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>20</td>
<td>71</td>
<td>27</td>
<td>Rectum</td>
<td>Poor</td>
<td>2.6</td>
<td>T1</td>
<td>2</td>
<td>0</td>
<td>8</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>21</td>
<td>25</td>
<td>22</td>
<td>Rectum</td>
<td>Moderate</td>
<td>5.5</td>
<td>T3</td>
<td>2</td>
<td>2</td>
<td>24</td>
<td>5</td>
<td>No</td>
</tr>
<tr>
<td>22</td>
<td>76</td>
<td>21</td>
<td>Rectum</td>
<td>Min. Resid. Foci*</td>
<td>n/a*</td>
<td>T2</td>
<td>1</td>
<td>0</td>
<td>14</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>23</td>
<td>52</td>
<td>24</td>
<td>Rectum</td>
<td>Moderate</td>
<td>3</td>
<td>T2</td>
<td>5</td>
<td>0</td>
<td>17</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>24</td>
<td>46</td>
<td>29</td>
<td>Rectum</td>
<td>Moderate</td>
<td>2</td>
<td>T3</td>
<td>2</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>Mean</td>
<td>62.7</td>
<td>26.9</td>
<td></td>
<td></td>
<td>4.0</td>
<td>3.0</td>
<td>15.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SLN = Sentinel Lymph Node, NIR = Near-Infrared, LN = Lymph Node, LN+ = Lymph Node with histologically proven metastases. Tumor Stage was determined by TNM classification. * Patient received neoadjuvant radiation and chemotherapy with a near complete pathological response.
mass. This phenomenon of lymph node effacement is well known for breast cancer patients. The fact that no fluorescence could be measured in the paraffin block of the lesion supports this hypothesis.

The great advantage of NIR fluorescence imaging is that the lymphatic channels traveling to the SLN are clearly visualized in real-time, even deep within the bowel mesentery. NIR fluorescence imaging also permits the use of small volumes (1 cc) of a colorless dye, and does not alter the appearance of the surgical field. Furthermore, the timing constraints of the technique we describe are very flexible, with successful identification of the SLN up to 1 hour after resection of the bowel.

These results and earlier findings suggest that NIR imaging has the potential to simplify the SLN procedure in colorectal cancer, when compared to the use of visible contrast agents like isosulfan blue. Therefore, larger studies comparing both techniques should be performed. The *ex vivo* approach has certain advantages, such as the use of contrast agents that are not yet approved for *in vivo* administration. The agent used in our study, HSA800, has previously been compared to clinically available agents like indocyanine green and methylene blue and has clear advantages over them. Due to conjugation of fluorophore IRDye 800CW to human serum albumin (HSA800), the hydrodynamic diameter of the probe increases from less than 1 to 7.4 nm, thereby facilitating a better retention in the first (sentinel) node as compared to blue dyes.

Because the agent is not injected into the patient, adverse reactions and patient safety are non-issues. Also, because the injection is performed after resection, it is not necessary that the surgeon performs the injection. Therefore, this technique does not add any time to the surgery, which is beneficial for the patient and could improve acceptance of the technique. In our hospital, the fluorescent dye is injected immediately after surgery at the department of pathology, thereby eliminating any interference with the surgical procedure. Using this technology, it should now be possible to design even more effective lymphatic tracers having higher fluorescence intensity and better lymph node retention.

The current NIR fluorescence imaging technique does not interfere with routine gross pathology and makes it possible to detect the SLN in sliced sections of rectal cancer specimens. Although neoadjuvant radiotherapy is known to affect lymphatic channels, even in rectal cancer patients that were treated with radiotherapy, SLNs were identified. A possible explanation is that only small amounts of HSA800 need to accumulate in the lymph node to be detected by the Mini-FLARE imaging system. As the mesorectum was not altered in any way, no lymphatic channels were disrupted. Furthermore, because lymph flow is induced by massaging the *ex vivo* specimen, decreased lymphatic flow can be overcome.

Compared to published clinical studies on SLN imaging using blue dyes, an important difference with the current study is the condition of the injection site. The current preclinical study was performed in healthy pigs, whereas the clinical application
of this technique was performed in cancer patients. Large tumors are especially known to alter and disrupt lymphatic channels. Since earlier studies show that there is still sufficient lymphatic flow to identify lymph nodes,\textsuperscript{12,37} we did not expect this to be a major problem. Viehl and colleagues showed that with larger tumors, a larger amount of blue dye (0.5 cc per cm tumor diameter) should be used to identify the SLN.\textsuperscript{37} This observation suggests an advantage for NIR fluorescence imaging, since in our pilot clinical study in which the mean diameter of the tumors was 4.5 cm, a smaller amount of dye (1 cc) was sufficient to be able to identify a fluorescent signal in the SLN.

In conclusion, our study suggests that \textit{ex vivo} SLN mapping using an optimal lymphatic tracer and invisible NIR fluorescent light permits real-time imaging of lymph flow and identification of the SLN in colon and rectal cancer specimens.

\textbf{ACKNOWLEDGEMENTS}

We thank Rita G. Laurence for assistance with animal anesthesia, Summer L. Gibbs-Strauss for cryo-sectioning, Lorissa A. Moffitt and Eugenia Trabucchi for administrative assistance and Daan J. Lips for technical assistance. This work was supported in part by NIH grant R01-CA-115296 (JVF), the Michæel van Vloten fund (AV), Foundation “De Drie Lichten” (MH), the Dutch Cancer Society (MH), Leiden University Fund (MH), Nuts Ohra Fund, Foundation “Maurits and Anna de Kock” and the Center for Translational Molecular Medicine (DeCoDe project, grant 03O-101).
REFERENCES
